SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
https://doi.org/10.14412/1995-4484-2018-667-670
Abstract
Enthesitis is inflammation at the site of attachment of tendon, ligament, or joint capsule to bone, a typical symptom of psoriatic arthritis (PsA). Heel enthesitis is of the greatest clinical significance. The activation of the interleukin 23/interleukin 17 (IL-23/IL-17) axis plays a pivotal role in the development of enthesitis. The latter can seriously limit the function of the musculoskeletal system and is incurable. If nonsteroidal anti-inflammatory drugs are ineffective, a biological agent should be immediately prescribed. The use of synthetic disease-modifying antirheumatic drugs for the treatment for enthesitis is not recommended due to their inefficacy. Despite the progress in the treatment of enteritis in PsA with tumor necrosis factor-α inhibitors, there is a need for the use of new drugs.
The paper describes the clinical case of a patient with PsA who has been successfully treated for isolated destructive enthesitis of the heel with the IL-17А inhibitor secukinumab (Cosentyx).
About the Authors
E. E. Gubar
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. Yu. Loginova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
T. V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Polachek A, Li S, Chandran V, Gladman DD. Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. Arthritis Care Res. 2017;69:1685-91. doi: 10.1002/acr.23174
2. Salvarani C, Cantini F, Olivieri I, et al. Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol. 1997;24(6):1106-10.
3. Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86 [Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.)]. doi: 10.14412/1995-4484-2017-68-86
4. Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73(2):437-45. doi: 10.1136/annrheumdis-2013-203643. Epub 2013 Aug 6.
5. Chimenti MS, Perricone C, Novelli L, et al. Interaction between microbiome and host genetics in psoriatic arthritis. Autoimmun Rev. 2018;17(3):276-83. doi: 10.1016/j.autrev.2018.01.002. Epub 2018 Feb 3.
6. Mease PJ, Karki C, Palmer JB, et al. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res. 2017;69(11):1692-9. doi: 10.1002/acr.23249
7. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337
8. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheum. 2016;68(5):1060-71. doi: 10.1002/art.39573
9. Antoni C, Krueger GG, de Vlam K, et al. IMPACT 2 Trial Investigators Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150-7. doi: 10.1136/ard.2004.032268
10. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147. doi: 10.1136/bmj.c147
11. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279-89. doi: 10.1002/art.21306
12. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebocontrolled study. Arthritis Rheum. 2009;60(4):976-86. doi: 10.1002/art.24403
13. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48-55. doi: 10.1136/annrheumdis-2013-203696
14. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40. doi: 10.1016/S0140-6736(09)60140-9. Epub 2009 Feb 11.
15. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and metaanalysis. Ann Rheum Dis. 2011;70:1895. doi: 10.1136/ard.2010.149419. Epub 2011 Sep 1.
16. Schoemaker MJ, Swerdlow AJ, Higgins CD, et al; UK Clinical Cytogenetics Group. Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study. Lancet Oncol. 2008;9(3):239-46. doi: 10.1016/S1470-2045(08)70033-0
17. Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol. 2017;4(4):272-7. doi: 10.5152/eurjrheum.2017.17037. Epub 2017 Nov 10.
18. Mease PJ, McInnes IB, Kirkham B, et al. FUTURE 1 Study Group Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329-39. doi: 10.1056/NEJMoa1412679
19. McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology. 2017;56(11):1993-2003. doi: 10.1093/rheumatology/kex301
Review
For citations:
Gubar E.E., Loginova E.Yu., Korotaeva T.V. SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS. Rheumatology Science and Practice. 2018;56(5):667-670. (In Russ.) https://doi.org/10.14412/1995-4484-2018-667-670
Views:
2601
Email this article 